Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis - Cao, Rui; Ma, Jie‐Tao; Zhang, Shu‐Ling; Sun, Li; Liu, Yang; Zhang, Xiang‐Yan; Jing, Wei; Huang, Le‐Tian; Han, Cheng‐Bo (Cancer medicine (Malden, MA), 2019)
Keywords: Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Biomarkers; Biomarkers, Tumor; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - etiology; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Clinical Cancer Research; Clinical trials; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - etiology; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Meta-analysis; Molecular Targeted Therapy - adverse effects; Molecular Targeted Therapy - methods; Monoclonal antibodies; Non-small cell lung carcinoma; nonsmall cell lung cancer; Original Research; PD-L1 protein; Pembrolizumab; programmed death‐ligand 1; Publication Bias; Remission Induction; Software; Studies; Targeted cancer therapy; Treatment Outcome; meta-analysis; programmed death-ligand 1; chemotherapy; nonsmall cell lung cancer; immunotherapy